Candida is the most common isolate of keratitis

Article

In a review of culture-positive fungal keratitis seen at Moorfields Eye Hospital, London, UK, over a 13-year period, Candida has been identified as the principal isolate.

In a review of culture-positive fungal keratitis seen at Moorfields Eye Hospital, London, UK, over a 13-year period, Candida has been identified as the principal isolate, according to the results of a study published in the October issue of Cornea.

Stephen Tuft and colleagues retrospectively identified isolates from laboratory reports and reviewed the clinical records. The fungal type, risk factors for infection, in vitro sensitivity and clinical outcome were recorded.

The researchers found 66 isolates from 65 patients, 40 of which were subspecies of Candida. The average interval from the onset of keratitis to confirmation of fungal infection was 3.4 weeks. Prior ocular surface disease or a penetrating keratoplasty (PK) was present in 97.4% of patients with Candida infection and 74.4% of patients with Candida infection were using topical steroids at the time of diagnosis.

The principal risk factors for filamentary fungal infection were trauma (30.8%) or cosmetic contact lens wear (30.8%), with ocular surface disease or a prior PK present in five (19.2%) cases.

The results of this review suggest that Candida is the principal isolate and is usually found in eyes with ocular surface disease or a prior PK treated with topical steroids.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.